EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa

Sida Liu, Susan J. Semple, Sylvia A. Sapula, Matthew Phanchana, Utid Suriya, Steven W. Polyak, Yang Chen, Hanbiao Chen, Judith M. Morton, Henrietta Venter

Frontiers in Pharmacology · 12.11.2026 · 17

DOI: 10.3389/fphar.2026.1979931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.11.2026. Verfasst von Sida Liu und 9 weiteren Autor:innen. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa : is one of the predominant pathogens associated with cystic fibrosis (CF) airway infections. Treatment is often challenging due to its intrinsic multidrug resistance, particularly because of the activity of tripartite resistance–nodulation–division (RND) drug efflux pumps such as the MexAB–OprM system. We have previously shown that ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in CF therapy, could enhance antibiotic activity against Escherichia coli through inhibition of the AcrB drug efflux protein. Given the high level of homology between the resistance-nodulation-division (RND) transporters from the drug efflux complexes, AcrB and MexB, the aim of this study was to investigate if ivacaftor could also synergise with antibiotics used to treat Pseudomonas aeruginosa infections in people with cystic fibrosis. Molecular dynamics simulation interrogated the interaction between ivacaftor and MexB. Thermal shift analysis and surface plasmon resonance were employed to determine the affinity of ivacaftor binding to MexB. The effects of ivacaftor on antibiotic susceptibility, efflux activity, and membrane integrity were investigated for reference strains and clinical P. aeruginosa strains isolated from people with CF. Our results predicted binding of ivacaftor to the distal binding site of MexB. Ivacaftor interacted with the RND transporters AcrB and MexB with a similar affinity as the efflux pump inhibitor (EPI) phenylalanine-arginine beta-naphthylamide (PAβN). Checkerboard assays demonstrated that ivacaftor restored susceptibility to several antibiotics currently used in anti-pseudomonal CF therapy, particularly aztreonam, ceftazidime, ciprofloxacin, and meropenem, while enhancing the antibiotic activity of azithromycin, erythromycin and minocycline. Nile Red efflux and Hoechst 33342 accumulation assays further supported inhibition of efflux activity by ivacaftor. Ivacaftor did not produce any off-target effects on the bacterial inner- or outer membrane. Overall, the results suggest that ivacaftor can function as an EPI in P. aeruginosa, thereby enhancing antibiotic activity. These findings support further investigation of CFTR modulators as adjunctive therapies against chronic infections caused by multidrug-resistant P. aeruginosa.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Liu, S., Semple, S. J., Sapula, S. A., Phanchana, M., Suriya, U., Polyak, S. W., Chen, Y., Chen, H., Morton, J. M., & Venter, H. (2026). Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1979931

Vancouver

Liu S, Semple SJ, Sapula SA, Phanchana M, Suriya U, Polyak SW, et al. Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1979931

BibTeX
@article{Liu2026,
  author = {Liu, Sida and Semple, Susan J. and Sapula, Sylvia A. and Phanchana, Matthew and Suriya, Utid and Polyak, Steven W. and Chen, Yang and Chen, Hanbiao and Morton, Judith M. and Venter, Henrietta},
  title = {Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1979931}
}
Kostenlos starten →